Ayala Pharmaceuticals, Inc. (ADXS)
OTCMKTS
· Delayed Price · Currency is USD
0.0300
0.00 (0.00%)
Mar 28, 2025, 11:46 AM EST
Ayala Pharmaceuticals Employees
As of December 31, 2023, Ayala Pharmaceuticals had 21 total employees, including 20 full-time and 1 part-time employees.
Employees
21
Change
n/a
Growth
n/a
Revenue / Employee
$619
Profits / Employee
-$2,289,143
Market Cap
2.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 21 | - | - |
Ayala Pharmaceuticals News
- 2 months ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire
- 2 months ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline - Business Wire
- 11 months ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
- 1 year ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
- 1 year ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
- 1 year ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire